Introduction
Obstructive lung diseases are one of the most common chronic diseases worldwide, and they are effectively controlled in most patients with a combination inhaler containing a corticosteroid and a long-acting β2 agonist (LABA). In patients with airway obstruction, evaluation of acute response to bronchodilators (the test of reversibility of airway obstruction) is a commonly used procedure in clinical and research studies. We know that the use of a combination inhaler containing budesonide and formoterol (BUD/FOR) to both maintenance and quick relief therapy has been recommended as an improved method of using inhaled corticosteroid/LABA. 1 There is no clear consensus on what constitutes reversibility or a significant acute response to a bronchodilator. The aim of this study was to examine the acute effects of using BUD/FOR and testing the availability of BUD/FOR for early reversibility test in patients with airway obstruction. Patients who had never used bronchodilators before, or; Patients who had not received short-or long-acting inhaled bronchodilator therapy within the recent 12 hours.
The study was performed in accordance with the ethical principles in the Good Clinical Practice guidelines, in addition to applicable local regulatory requirements, and the protocol was approved by local Bahcesehir University Clinical Research Ethics Committee. The patients were informed of the study procedure, and written informed consents were obtained.
Pulmonary function test and reversibility assessment
The values of basal FVC, FEV 1 , FEV 1 /FVC, peak expiratory flow (PEF), and forced expiratory flow 25%-75% (FEF 25%-75%) were measured using the MIR (MIR Medical International Research Srl, Rome, Italy) MiniSpir PC-Based USB Spirometer by the same physician (Sevket Ozkaya) following a 30-minute resting period in an outpatient clinic setting. The test was performed in the seated position, when the nose was clamped and nasal respiration was hindered. The patients performed the forced expiratory maneuver at least three times, and the maximum FEV 1 value was recorded as the basal value. 
reversibility test

statistical assessment
Results were presented as means ± standard errors of means. The probability P,0.05 was considered significant. Descriptive group data were compared using the unpaired Student's t-test and Pearson chi-square test.
Results
A total of 44 patients were included in the study. The patients' demographic data and baseline pulmonary function test results are shown in 
Discussion
There is no consensus on which bronchodilator drug should be used for the reversibility test. The reversibility test might be performed using metered-dose inhaled bronchodilators, dry powder inhaler, and metered-dose inhaled bronchodilators through an air chamber or nebulizer. 2 Although the shortacting beta-2 agonists, salbutamol (SLB) and terbutaline, are the most commonly used bronchodilators for early reversibility test, the fixed combination of long-acting beta-2 agonist (LABA) plus inhaled steroid drugs are used in the treatment of patients with airway obstruction. LABA plus inhaled steroid drugs have also been reported to act in short term. In our previous study, the positive reversibility test with SLB was found in 61.9% of patients. 3 Another study that compared the fixed combination of BUD/FOR (320/9 µg) with SLB reported that the positive reversibility test was higher in BUD/FOR group (50%) than in SLB group (20%). 4 In the present study, the reversibility was positive in 26 (59.1%) patients. Recent study suggested a new approach for acute exacerbation -SMART (single inhaler maintenance and reliever therapy). This uses the combination inhaler, rather than the short-acting β2 agonist, as the reliever. [5] [6] [7] We examined the relationship between reversibility and change in values of FVC, FEV 1 , PEF, and FEF (25%-75%). Only the absolute change and percentage of change in mean FEV 1 were statistically significant (P#0.05). These findings show that FEV 1 is a true parameter for the evaluation of reversibility.
We used the short-acting beta-2 agonists (usually SLB) and a combination inhaler containing a corticosteroid plus a LABA for early and late reversibility tests in patients with airway obstruction, respectively. Also, we prescribed a combination inhaler containing a corticosteroid plus a LABA (usually BUD/FOR) for patients with airway obstruction, and trained the patients in the correct usage of inhaler devices. These results authenticate the idea of using a combination inhaler containing a corticosteroid and a LABA for early reversibility test. This study proves that a fixed combination of BUD/FOR can be used in early reversibility testing. Further studies are required to support this result.
Conclusion
The following results are observed regarding the usage of fixed combination of BUD/FOR in early reversibility test. They are fast acting. They can be used for early reversibility test (not only for treatment). The procedure contributes to the patients in the training of using inhaler devices during spirometry. Patients can immediately see the effects of the Drug Design, Development and Therapy
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